ADHD Expert Column Series

 
 
  • Role of Behavioral Therapies for Attention-Deficit/Hyperactivity Disorder Which behavioral approaches are most helpful for patients with ADHD? Who benefits most from these interventions? When should they be adjuncts to medication, and when are they effective on their own?
  • The Role of Alpha 2 Agonists in ADHD Treatment Up to 35% of patients with ADHD do not benefit from or cannot tolerate stimulant agents. Can alpha agonists help to fill the gap?
  • Stimulants and Risk for SUD The bulk of evidence shows that stimulant treatment does not cause SUD in patients with ADHD. But the relationships among risk factors are complicated. Scott Kollins, PhD, clarifies the controversy.
  • Understanding Effect Size Effect size has become an important component in evaluating various treatment strategies. But what does it really signify?
  • Alpha-2 Agonists in ADHD How do weakened prefrontal cortical circuits cause ADHD symptoms? Which agents strengthen this network? Can targeted treatment improve working memory and executive function?
  • Treating ADHD in Adults With Comorbid Mood Disorders How does ADHD affect the symptoms of comorbid mood disorders and their prognosis? Which approaches provide the most effective management?
  • ADHD in Children With Comorbid Conditions Psychiatric comorbidity is seen in 50% to 90% of children with ADHD. What characteristics differentiate ADHD from the co-occurring disorder? Which should be treated first?
  • The Impact of Stimulant Abuse, Misuse, and Diversion on Clinical Practice Does exposure to stimulants cause or protect against substance abuse among patients with ADHD? What clinical approaches provide opimal treatment and minimal risk for both?
  • Depression and ADHD: What You Need to Know More than 30% of patients with depression have comorbid ADHD, and symptoms of the 2 disorders can overlap. How can you distinguish one from the other when they co-occur? What treatments work for both?
  • Recognizing and Managing Stimulant Complications Noncompliance rates for stimulants can reach as high as 65%, primarily because of side effects. How can you minimize adverse events to maximize adherence and effectiveness of treatment?
  • The Genetics of Attention-Deficit/Hyperactivity Disorder Which genes increase susceptibility to ADHD? How can genetic variants alter a person's response to stimulant treatment?
  • Differential Diagnosis of ADHD in School-Age Children A variety of medical and psychiatric disorders cause symptoms that can mimic ADHD in young children. What key questions, lab tests, and physical clues will help narrow the differential?
  • ADHD and Substance Use Disorders What is the association between ADHD and substance use disorders? Can you safely prescribe stimulants to patients with these comorbidities?
  • New-Generation Long-Acting Stimulants for the Treatment of ADHD Special review of stimulant medication for ADHD
  • Understanding the Effect Size of ADHD Medications By knowing the different measures and how they are computed, clinicians can sensibly read the literature and better understand the results of medication studies.
  • The Long-term Safety of Stimulant Treatment A synthesis of recent literature on 3 areas of concern in chronic stimulant treatment: effects on growth, tics, and cardiovascular parameters.
  • ADHD and Substance Abuse Is there a connection between ADHD and substance abuse?
  • Adolescence and ADHD Understanding ADHD in the context of adolescence
  • ADHD: A Common Diagnosis? Attention deficit/hyperactivity disorder(ADHD)is one of the most common psychiatric disorders of childhood and adolescence.